{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:45:16Z","timestamp":1794606316479,"version":"4.9.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.ejca.2024.113525","type":"journal-article","created":{"date-parts":[[2024,1,6]],"date-time":"2024-01-06T16:39:31Z","timestamp":1704559171000},"page":"113525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing\/refractory solid tumors"],"prefix":"10.1016","volume":"198","author":[{"given":"Nicolas","family":"Andr\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie C\u00e9cile Le","family":"Deley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e9mence","family":"L\u00e9guillette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Probst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1230-1049","authenticated-orcid":false,"given":"Leen","family":"Willems","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Travers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Faure-Conter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Revond-Riviere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Geoerger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Chastagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natascha","family":"Entz-Werl\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7088-2614","authenticated-orcid":false,"given":"Pierre","family":"Leblond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2024.113525_bib1","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10654-018-0370-3","article-title":"The PanCareSurFup cohort of 83,333 five-year survivors of childhood cancer: a cohort from 12 European countries","volume":"33","author":"Grabow","year":"2018","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.ejca.2024.113525_bib2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2024.113525_bib3","first-page":"121","article-title":"Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial","volume":"21","author":"Geoerger","year":"2020"},{"key":"10.1016\/j.ejca.2024.113525_bib4","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejca.2017.09.032","article-title":"Phase II study of ipilimumab in adolescents with unresectable stage III or IV malignant melanoma","volume":"86","author":"Geoerger","year":"2017","journal-title":"Eur J Cancer"},{"issue":"8","key":"10.1016\/j.ejca.2024.113525_bib5","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1093\/neuonc\/noad031","article-title":"Nivolumab with or without ipilimumab in pediatric patients with high-grade CNS malignancies: Safety, efficacy, biomarker, and pharmacokinetics-CheckMate 908","volume":"25","author":"Dunkel","year":"2023","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2024.113525_bib6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1470-2045(19)30693-X","article-title":"Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study","volume":"21","author":"Geoerger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2024.113525_bib7","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(20)30023-1","article-title":"Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial","volume":"21","author":"Davis","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2024.113525_bib8","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.66.6552","article-title":"Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency","volume":"34","author":"Bouffet","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113525_bib9","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1158\/1078-0432.CCR-22-2164","article-title":"A phase I\/II trial of nivolumab plus ipilimumab in children and young adults with relapsed\/refractory solid tumors: a Children's Oncology Group Study ADVL1412","volume":"28","author":"Davis","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2024.113525_bib10","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1093\/annonc\/mdz297","article-title":"Combinatorial immunotherapy strategies: most gods throw dice, but fate plays chess","volume":"30","author":"Ciccolini","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2024.113525_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions.","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2024.113525_bib12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.trecan.2017.03.011","article-title":"Metronomic chemotherapy: direct targeting of cancer cells after all?","volume":"3","author":"Andr\u00e9","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ejca.2024.113525_bib13","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2024.113525_bib14","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"6","key":"10.1016\/j.ejca.2024.113525_bib15","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210831","article-title":"Taking regulatory T cells into medicine","volume":"218","author":"Sakaguchi","year":"2021","journal-title":"J Exp Med"},{"key":"10.1016\/j.ejca.2024.113525_bib16","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2024.113525_bib17","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.27990","article-title":"Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer","volume":"133","author":"Shevchenko","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2024.113525_bib18","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1158\/0008-5472.CAN-13-0545","article-title":"Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells","volume":"73","author":"Park","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.113525_bib19","first-page":"4425","article-title":"Early-phase treatment by low-dose 5-fluorouracil or primary tumor resection inhibits MDSC-mediated lung metastasis formation","volume":"35","author":"Otsubo","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2024.113525_bib20","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1158\/0008-5472.CAN-09-3690","article-title":"5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity","volume":"70","author":"Vincent","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.113525_bib21","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.intimp.2013.10.019","article-title":"Antitumor effects of anti-CD40\/CpG immunotherapy combined with gemcitabine or 5-fluorouracil chemotherapy in the B16 melanoma model","volume":"17","author":"Qu","year":"2013","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.ejca.2024.113525_bib22","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.130748","article-title":"Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells","volume":"4","author":"Peereboom","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejca.2024.113525_bib23","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ccell.2015.10.012","article-title":"Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents","volume":"28","author":"Galluzzi","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2024.113525_bib24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s13402-010-0005-5","article-title":"Chemotherapeutic agents in low noncytotoxic concentrations increase immunogenicity of human colon cancer cells","volume":"34","author":"Kaneno","year":"2011","journal-title":"Cell Oncol"},{"key":"10.1016\/j.ejca.2024.113525_bib25","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1158\/0008-5472.CAN-09-1106","article-title":"Dual therapeutic efficacy of vinblastine as a unique chemotherapeutic agent capable of inducing dendritic cell maturation","volume":"69","author":"Tanaka","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2024.113525_bib26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4049\/jimmunol.0900734","article-title":"Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism","volume":"183","author":"Shurin","year":"2009","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.ejca.2024.113525_bib27","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1158\/2159-8290.CD-21-1136","article-title":"The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies","volume":"12","author":"Berlanga","year":"2022","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.ejca.2024.113525_bib28","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26832","article-title":"A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas","volume":"65","author":"Kilburn","year":"2018","journal-title":"Pedia Blood Cancer"},{"key":"10.1016\/j.ejca.2024.113525_bib29","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.00557","article-title":"Immune checkpoint inhibitor-related cytokine release syndrome: analysis of WHO global pharmacovigilance database","volume":"11","author":"Ceschi","year":"2020","journal-title":"Front Pharm"},{"key":"10.1016\/j.ejca.2024.113525_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2021.121334","article-title":"A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy.","volume":"281","author":"Maharjan","year":"2022","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.ejca.2024.113525_bib31","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.3390\/cancers13081901","article-title":"Immunotherapy combined with metronomic dosing: an effective approach for the treatment of NSCLC","volume":"13","author":"Skavatsou","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2024.113525_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100646","article-title":"MOVIE: a phase I, open-label, multicenter study to evaluate the safety and tolerability of metronomic vinorelbine combined with durvalumab plus tremelimumab in patients with advanced solid tumors","volume":"7","author":"Vicier","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejca.2024.113525_bib33","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2017.00792","article-title":"Sustained Complete Response to Metronomic Chemotherapy in a Child with Refractory Atypical Teratoid Rhabdoid Tumor: A Case Report.","volume":"8","author":"Berland","year":"2017","journal-title":"Front Pharm"},{"key":"10.1016\/j.ejca.2024.113525_bib34","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3390\/jcm12041415","article-title":"Retrospective National \"Real Life\" Experience of the SFCE with the Metronomic MEMMAT and MEMMAT-like Protocol","volume":"12","author":"Winnicki","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.ejca.2024.113525_bib35","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2023.4437","article-title":"I. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial","author":"Peyrl","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ejca.2024.113525_bib36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejca.2021.03.032","volume":"150","author":"Pasqualini","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2024.113525_bib37","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1007\/s00262-022-03159-8","article-title":"Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1\/2 trial.","volume":"71","author":"Loeb","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2024.113525_bib38","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2018.00950","article-title":"Metronomic Four-Drug Regimen Has Anti-tumor Activity in Pediatric Low-Grade Glioma; The Results of a Phase II Clinical Trial","volume":"9","author":"Verschuur","year":"2018","journal-title":"Front Pharm"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000017?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804924000017?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T20:35:52Z","timestamp":1721680552000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804924000017"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":38,"alternative-id":["S0959804924000017"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113525","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"METRO-PD1: Phase 1 study of nivolumab in combination with metronomic chemotherapy in children and adolescents with relapsing\/refractory solid tumors","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2024.113525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"113525"}}